--- title: "U.S. stock market update: Sellas Life Sciences up 17.27%, receives $56 million collaboration funding from Jazz" type: "News" locale: "en" url: "https://longbridge.com/en/news/291169405.md" description: "Sellas Life Sciences rose 17.27%; AbbVie rose 0.53%, with a transaction volume of USD 696 million; Revolution Medicines rose 1.51%, with a transaction volume of USD 303 million; Moderna rose 1.07%, with a transaction volume of USD 229 million; Amgen rose 0.36%, with a market capitalization of USD 194.1 billion" datetime: "2026-06-29T15:42:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291169405.md) - [en](https://longbridge.com/en/news/291169405.md) - [zh-HK](https://longbridge.com/zh-HK/news/291169405.md) --- # U.S. stock market update: Sellas Life Sciences up 17.27%, receives $56 million collaboration funding from Jazz **U.S. Stock Market Midday Update** Sellas Life Sciences rose by 17.27%. Based on recent key news: 1. On June 26, Sellas Life Sciences' stock price increased by 17.56%, primarily due to its product line including peptide immunotherapy targeting the WT1 antigen and selective small molecule CDK9 inhibitors, driving stock price volatility and trend changes. Data source: Benzinga. 2. On June 26, Sellas' stock price approached a 52-week high of $11.06, with technical charts indicating key resistance and support levels at $11.06 and $8.54, respectively, affecting trading behavior. Data source: Benzinga. 3. On June 29, Sellas entered into a collaboration agreement with Jazz Pharmaceuticals, securing $56 million in upfront funding, which boosted the stock price. Data source: Benzinga. The biotechnology industry is experiencing increased volatility, with significant capital inflow. **Stocks with High Trading Volume in the Industry** AbbVie rose by 0.53%. Based on recent key news: 1. On June 26, AbbVie announced the acquisition of Apogee Therapeutics, driving the stock price up. Following the announcement, AbbVie saw an intraday increase of 1.6%, currently reported at $247.03. 2. On June 29, AbbVie received a positive opinion from the European Medicines Agency (CHMP) for Rinvoq (upadacitinib) 15mg for adults and adolescents with non-segmental vitiligo. The approval of this drug will make it the first systemic treatment for vitiligo, boosting the stock price. 3. On June 29, AbbVie's partner Regenxbio administered its treatment for diabetic retinopathy in a late-stage study for the first time, receiving a $100 million milestone payment. This news propelled Regenxbio's stock price up by 5.9%. Investor interest in the biopharmaceutical industry is rebounding, with strong market performance. Revolution Medicines rose by 1.51%. Based on recent key news: 1. On June 26, analysts raised the target price for Revolution Medicines to $188.57, indicating a potential upside of about 11%. Analysts unanimously rated it as "Buy," driving the stock price up. Source: FactSet. 2. On June 27, Revolution Medicines' innovative drug completed clinical development, with market expectations that it will become the next successful commercialized Biopharma company, enhancing investor confidence. Source: Zhitong Finance. 3. On June 29, Revolution Medicines' drug continued to generate stable cash flow post-launch, reducing reliance on equity financing and further solidifying its market position. Source: Zhitong Finance. The Biopharma industry is accelerating its independent commercialization process Moderna rose by 1.07%. Based on recent key news: 4. On June 27, Piper Sandler raised Moderna's target price from $69 to $77, driving the stock price up. 5. On June 26, the FDA advisory panel unanimously recommended the approval of Moderna's mRNA influenza vaccine mRNA-1010, which became a major catalyst for the stock price increase. 6. On June 25, Moderna showcased progress in cancer prevention, autoimmune diseases, and next-generation mRNA therapies during its Science Day event, further boosting market confidence. Moderna's stock price is close to its 52-week high, with increased trading volume. **Stocks ranked among the top in industry market capitalization** Amgen rose by 0.36%. Based on recent key news: 1. On June 26, the European Medicines Agency recommended the withdrawal of Amgen's market authorization for the rare disease drug Tavneos. This move was due to the risks of the drug outweighing its benefits, putting pressure on Amgen's stock price. 2. On June 26, the U.S. FDA identified 76 cases of severe liver injury associated with Tavneos and recommended the withdrawal of its approval in the U.S. This news further heightened market concerns about Amgen. 3. On June 27, Amgen was listed as one of the top three holdings in the SCHD ETF, driving its stock price up. This news indicates that investors still have confidence in Amgen's long-term growth potential. The pharmaceutical industry faces regulatory risks, with significant capital inflow ### Related Stocks - [SLS.US](https://longbridge.com/en/quote/SLS.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Moderna posts smaller-than-expected Q2  loss per share on lower R&D spending](https://longbridge.com/en/news/294503814.md) - [Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For](https://longbridge.com/en/news/294593887.md) - [Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For](https://longbridge.com/en/news/294635736.md) - [MRNA: Q2 2026 saw modest revenue growth, improved expense outlook, and key pipeline milestones](https://longbridge.com/en/news/294503500.md) - [Moderna (MRNA) Beat Revenue Views, Is The Stock Now Too Expensive?](https://longbridge.com/en/news/294387965.md)